- Home
- ES vs RPRX Comparison
ES vs RPRX Comparison
Compare ES & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ES | RPRX |
|---|---|---|
| Founded | 1927 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.1B | 25.9B |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ES | RPRX |
|---|---|---|
| Price | $70.83 | $60.82 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 5 |
| Target Price | ★ $71.00 | $51.40 |
| AVG Volume (30 Days) | 1.8M | ★ 2.6M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.58% | 1.90% |
| EPS Growth | ★ 100.88 | N/A |
| EPS | ★ 1.75 | 0.71 |
| Revenue | ★ $13,547,244,000.00 | $2,378,193,000.00 |
| Revenue This Year | N/A | $38.63 |
| Revenue Next Year | $3.77 | $4.73 |
| P/E Ratio | ★ $40.47 | $85.70 |
| Revenue Growth | ★ 13.83 | 5.06 |
| 52 Week Low | $62.45 | $34.63 |
| 52 Week High | $76.57 | $62.46 |
Technical Indicators
Market Signals| Indicator | ES | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.57 | 59.89 |
| Support Level | $70.62 | $56.36 |
| Resistance Level | $71.30 | N/A |
| Average True Range (ATR) | 1.06 | 1.27 |
| MACD | -0.07 | 0.16 |
| Stochastic Oscillator | 34.38 | 74.68 |
Price Performance
Historical ComparisonAbout ES Eversource Energy (D/B/A)
Eversource Energy is a diversified holding company with subsidiaries that provide rate-regulated electric, gas, and water distribution service to more than 4 million customers in the Northeast US. Eversource expanded its service territories with acquisitions of NStar (2012), Aquarion (2017), and Columbia Gas (2020). In 2024 Eversource exited its 50% partnership with European utility Orsted to develop 2 gigawatts of offshore wind projects in the Northeast US. It plans to sell Aquarion in 2026. The company exited most of its unregulated businesses in 2006.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.